CLGN$4.24+3.92%
CollPlant Biotechnologies Ltd
Sector: Orthopedic, Prosthetic & Surgical Appliances & SuppliesIndustry: BiotechnologyCountry: ILExchange: Nasdaq
Mkt Cap:$10.37M
Float & O/S:
Inst Own:
DilutionScan read 55 of CollPlant Biotechnologies Ltd's SEC filings and found 24 warrant series, 3 shelf registrations, 2 S-1 registrations and 4 completed offerings on file for CLGN. The latest dilution event on file is an offering on Oct 14, 2026. Analysis updated Nov 2, 2026.
Signal8 Summary
CLGN
Going-concern warning, cash running out
Snapshot
CollPlant is a tiny biotech with $2.4M in FY 2025 revenue and a $11.5M net loss, funded mostly by a $8.2M R&D budget. It burned $9.4M in free cash flow against just $6.0M in cash, and the company itself has said that isn't enough to run for the next 12 months.
What's Happening Right Now
- : On August 31, 2026, CollPlant announced it is acquiring LightSolver, a photonic computing company, moving the company into supercomputing and photonic computing markets.
- : CollPlant is seeking shareholder approval for a reverse stock split of 1-for-8 to 1-for-12 after receiving a Nasdaq non-compliance notice in March 2026 for trading below the $1.00 minimum bid price.
- : CollPlant filed a prospectus supplement on July 22, 2026 warning it does not have enough cash to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
- : CollPlant filed an F-3 shelf registration on July 10, 2026 covering resale of over 31 million shares, disclosing insufficient cash to operate for 12 months and that it has begun evaluating strategic alternatives including acquisitions.
- : On June 30, 2026, CollPlant priced a $2.6 million private placement of shares and warrants at $0.34 per share, with proceeds earmarked for general corporate purposes, R&D, and evaluating strategic combinations.
